A group of scientists from Harvard University have observed and reconstructed the human brain at the resolution of the electron microscope, with all its cells, following all the connections between its neurons around a cubic millimeter of a tissue sample. They took 10 years and the data occupies 1.4 petabytes (1,400 terabytes). However, they are already planning a bigger project.
A group of scientists from Harvard University have observed and reconstructed the human brain at the resolution of the electron microscope, with all its cells, following all the connections between its neurons around a cubic millimeter of a tissue sample. They took 10 years and the data occupies 1.4 petabytes (1,400 terabytes). However, they are already planning a bigger project.
HERV-H LTR-associating protein 2 (HHLA2) is known to play immunosuppressive roles by interacting with killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3). The expression of HHLA2 in cancer is associated with poor patient outcomes, making it a promising therapeutic target for immunotherapy. Nextpoint Therapeutics Inc. has presented data on their monoclonal antibodies NPX-267 and NPX-887, which target KIR3DL3 and HHLA2, respectively.
CSPC Pharmaceutical Group Ltd.’s anti-βKlotho monoclonal antibody drug JMT-202 has received clearance from China’s National Medical Products Administration (NMPA) to enter clinical trials to lower triglyceride levels in patients with hypertriglyceridemia.
The recent cyberattack on Change Healthcare, a part of the Unitedhealth Group, crippled reimbursement claims processing for thousands of providers for several weeks and potentially exposed troves of patient data. Congressional committees are investigating the attack, its scope, and Unitedhealth’s response. Please take a few minutes to fill out this short survey to help BioWorld understand how your company is responding to these threats. You can click through to the questions here.
Kalvista Pharmaceuticals Ltd. has disclosed coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of hereditary angioedema and thrombotic disorder.
Kate Therapeutics Inc. recently presented data on a novel muscle- and heart-targeted, liver de-targeted development candidate for the treatment of Duchenne muscular dystrophy (DMD) – KT-809.
Researchers from Ikarovec Ltd. have presented preclinical data for the AAV8-IKC159V, the company’s lead bicistronic gene therapy being developed for the treatment of geographic atrophy, a late stage of geographic dry AMD.
Breast cancer is a heterogenous disease in terms of its prognosis and treatment response. Metabolic reprogramming is a potential therapeutic target because of its repercussion on oncogenesis.
The success of a vaccine, a gene editing design for an untreated disease, or achieving cell engraftment after several attempts, comes from years of accumulated basic science studies, thousands of experiments, and clinical trials. Innumerable steps precede hits in gene and cell therapies before a...
Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.
By isolating a single clone from human isolates, researchers from the National Taiwan University College of Medicine aimed to enhance the immunogenicity of the Zika virus (ZIKV).
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized 3C-like proteinase (3CLpro, Mpro) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome infections.
The Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately ¥1.64 billion (US$10.8 million) in four projects for the development of new drugs for malaria and neglected tropical diseases.
Merck Sharp & Dohme LLC has patented potassium voltage-gated channel subfamily C member 1 (Kv3.1; KCNC1) activators reported to be useful for the treatment of neurological and psychiatric disorders.
4M Therapeutics Inc. has announced the presentation of preclinical data on its small-molecule glycogen synthase kinase-3β (GSK-3β) inhibitors in models of bipolar disorder.
Macrophage colony-stimulating factor 1 receptor (CSF-1R) is a transmembrane tyrosine kinase receptor expressed in brain microglia, and mutations in the CSF1R gene have been linked to adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
A Tisento Therapeutics Inc. patent describes new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, vascular dementia, ischemic stroke, Leigh syndrome, Pearson syndrome, creatine deficiency syndrome and Alpers syndrome, among...
Norwegian University of Science and Technology (NTNU) has synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, macular degeneration,...
Centogene NV and Evotec SE have announced the discovery of a new small molecule with potential to treat patients with type 2 and type 3 Gaucher disease, or neuronopathic Gaucher disease.
Researchers from Tokyo Medical University presented data from a study that assessed microRNA (miRNA) profiles in extracellular vesicles (EVs) isolated from vitreous humor and serum of patients with ocular sarcoidosis and vitreoretinal lymphoma (VRL).
Recent findings discovered a mutation in the METTL23 gene, which encodes methyltransferase-like protein 23, in a pedigree of normal-tension glaucoma (NTG). The aim of researchers from the Institute for Vision Research, The University of Iowa Roy J and Lucille A Carver College of Medicine was to...
Aqilion AB has expanded its pipeline through the nomination of protein kinase C θ (PKCθ) as the target of a new immunology project. The PKCθ kinase is believed to be centrally involved in the pathogenesis of T-cell-mediated inflammatory and...
Pfizer Inc. has divulged 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17- β-HSD 13) inhibitors and/or degraders reported to be useful for the treatment of hepatocellular carcinoma, biliary cirrhosis, hepatitis B and hepatitis C viral...
Virginia Commonwealth University has identified cholestenoic acid derivatives reported to be useful for the treatment of cancer, sepsis, atherosclerosis and nonalcoholic fatty liver disease (NAFLD; metabolic dysfunction-associated steatotic liver...
Synedgen Inc. has completed IND-enabling studies for its lead candidate, MIIST-305, which is being developed for ulcerative colitis and as a medical countermeasure for gastrointestinal acute radiation syndrome. Within a year, Synedgen plans to...
Ochre Bio Ltd. has established a partnership with Boehringer Ingelheim Pharma GmbH & Co. KG focused on the discovery and development of novel first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic...
New York University has described protein spinster homolog 2 (SPNS2) inhibitors reported to be useful for the treatment of acute lung injury, autoimmune disease, colitis, Alzheimer’s disease, fibrosis, inflammatory bowel disease, multiple...
Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.